Researchers at Stanford University have developed a new device for connecting the brain directly to silicon-based technologies. While brain-machine interface devices already exist—and are used for prosthetics, disease treatment and brain research—this latest device can record more data while being less intrusive than existing options.
Read More
https://techxplore.com/news/2020-03-device-silicon-power-brain-prosthetics.html
Views: 0
In this recent webcast, Rich Powers, head of ETF Product Management and Tim Holmes, head of Equities, ETFs, and Options Trading for individual investors, will help to demystify and simplify ETFs and answer your questions.
Read More
https://investornews.vanguard/why-all-the-talk-about-etfs/
Views: 0
During its 63rd session, the Commission on Narcotic Drugs (CND) accepted all recommendations from the 42nd meeting of the WHO Expert Committee on Drug Dependence (ECDD). This effectively brings twelve psychoactive substances, including eleven New Psychoactive Substances (NPS) and one medicine, under international control. Given the potential for dependence or abuse and known adverse effects, these compounds pose a risk to public health and society and are largely without any therapeutic benefit.
Based on an in-depth review of candidate compounds by the ECDD, an independent group of experts in the field of drugs and medicines, the WHO provides annual recommendations on substance scheduling to the CND, a policy-making body comprised of 53 UN Member States. This ECDD review includes a balanced consideration of potential for abuse, dependence and harm with therapeutic value. The CND then votes on whether or not the WHO recommendations for placing reviewed substances under international control should be endorsed.
The 42nd ECDD recommendations included the addition of four synthetic cannabinoids and three synthetic stimulants to Schedule II of the 1971 Convention on Psychotropic Substances given similar action and adverse effects to other substances in this Schedule. These synthetic cannabinoids have been associated with impaired mental status, impaired driving, and fatalities, whereas the included synthetic stimulants have been linked to fatal intoxication. Similarly, two fentanyl analogues, with their opioid-like effects, were brought under Schedule I control (strict control) of the 1961 Single Convention on Narcotic Drugs given similar action and effects to other drugs in this Schedule. Two benzodiazepines including the medicine etizolam were brought under Schedule IV control of the 1971 Convention on Psychotropic Substances, both of which have been implicated in fatal and non-fatal intoxication and impaired driving. A hallucinogen was also recommended to be brought under control, specifically to Schedule I of the Convention on Psychotropic Substances of 1971, based on abuse potential and non-fatal and fatal intoxication. This is the first hallucinogen to be reviewed in many years, suggesting a potential shift in drug trends. For more information on these recommendations, please review the 42nd ECDD meeting report. .
In addition, the ECDD conducted a pre-review of several Schedule III opioid preparations, some of which can be accessed as over-the-counter options, such as codeine-based cough syrups, to consider their abuse potential. The ECDD recommended a critical review be carried out at a later date.
Read More
https://www.who.int/news-room/detail/18-03-2020-c-n-d-accepts-all-w-h-o-recommendations-from-42nd-e-c-d-d
Views: 0
See details about the retirement options, including some if you’re self-employed.
Read More
https://investornews.vanguard/no-401k-at-work-heres-how-you-can-save-for-retirement/
Views: 0
Feeling unsure about your college savings plans? Even the savviest of savers can become bewildered when considering college savings options. In part 2 of this 2-part podcast, Maria and Joel tackle this topic, discussing the different types of 529 plans and how to navigate financial aid, gift contributions, assets, and taxes.
Read More
https://investornews.vanguard/navigating-college-savings-part-2/
Views: 0
Lightweight technology has long been and is sure to remain a mainstay of automotive and aerospace engineering, shipbuilding and a host of other industries. Lighter materials and components could also help cut emissions that drive climate change. But lighter options are pricier, and the relatively steep cost has impeded their adoption. That is about to change thanks to the efforts of a consortium of automakers, suppliers and research institutes. Called ALLIANCE and coordinated by Daimler and the Fraunhofer Institute for Structural Durability and System Reliability LBF, this project has some good news for designers: As it turns out, it is entirely possible to build components that are up to 33 percent lighter at an added cost of less than three euros per kilogram-saved.
Read More
Views: 0
Women who are pregnant or breastfeeding in an Ebola outbreak face similar challenges as other population groups, but they have specific health needs which must be met.
As the second largest Ebola outbreak in history continues in the Democratic Republic of Congo, WHO has released new clinical guidelines for healthcare providers supporting pregnant or breastfeeding women in the context of Ebola virus disease.
Clear and coherent guidance is needed to meet the combined needs of women requiring Ebola treatment, pregnancy care and management of complications.
Information on how to protect breastfeeding children and other members in the community from transmission of the disease is also critical.
Limited scientific evidence on how to best manage these needs has previously been a challenge for affected countries. In addition, misconceptions that pregnant women have a higher mortality rate than other populations with Ebola may in some contexts have put pregnant women at risk of not receiving standard care.
WHO’s Guideline on the management of pregnant and breastfeeding women in the context of Ebola virus reviews existing evidence and provides a single set of recommendations on the care continuum for women exposed to, diagnosed with, or recovered from Ebola.
This will enable healthcare providers, emergency response teams and health policy-makers to improve prevention and treatment measures in an Ebola outbreak.
Optimal supportive care should be offered to all pregnant women with Ebola. Likewise, they should be offered experimental treatment and vaccination under the same conditions as non-pregnant populations.
Ebola virus disease does increase the risk of miscarriage and early labour, requiring close clinical management at Ebola treatment centres. It is important to engage both obstetric providers and those trained in Ebola response.
This dual expertise is also important because early Ebola and pregnancy-related symptoms can overlap. Pregnant women should be prioritised for testing to confirm an Ebola infection.
Ebola virus can persist in pregnancy related fluids as well as breastmilk. If healthcare providers are not clear on how to manage Ebola infection risk, they may be less willing to provide care. This stigma can be life-threatening for women who experience complications during delivery.
The new WHO guidelines advise healthcare workers on how to protect themselves while caring for pregnant women with Ebola virus disease. This includes induced labour or surgical procedures, which carry greater risk of transmission in cases of acute infection. Any invasive treatments should be carried out in full personal protective equipment.
WHO recommends that women with suspected or confirmed Ebola immediately stop breastfeeding and are prioritised for diagnostic testing. Any child exposed to Ebola through breast milk should be placed into safe care, closely monitored for symptoms over a 21-day period and fed with an appropriate breast milk substitute.
The guidelines strongly recommend that breastfeeding is only restarted following two consecutive negative tests of breast milk, separated by 24 hours.
A breast milk substitute should be used even if infection is confirmed for both the mother and her child. Exceptions can be made for infants under 6 months of age who are already infected, if breast milk substitutes are not feasible, affordable, sustainable or safe and separation cannot be implemented safely.
A disease outbreak does not change women’s and adolescent girls’ fundamental human right to sexual and reproductive healthcare, including evidence-based care during pregnancy and childbirth.
Women need support to make informed reproductive health care choices for themselves and their children. Women living in an Ebola outbreak should have access to all relevant reproductive options, regardless of economic, cultural, racial or religious status, including contraception and safe abortion to the full extent of the law.
Pregnant and breastfeeding women across affected communities need equitable and respectful care that considers the risks they face and supports the choices they make.
These guidelines are now available online and may be freely downloaded. The executive summary will be available in French.
WHO will closely monitor new data as it emerges, as there is still a pressing need to prioritise ongoing research related to Ebola virus transmission.
Read More
https://www.who.int/news-room/detail/10-02-2020-pregnancy-and-breastfeeding-during-an-ebola-virus-outbreak
Views: 0